Loading...
•
Feb 29, 2024
AngioDynamics Q3 2024 Earnings Report
Announced fiscal year 2024 third quarter results and updated fiscal year 2024 guidance to reflect asset divestiture.
Key Takeaways
AngioDynamics reported an 8.0% increase in net sales to $66.0 million for the third quarter of fiscal year 2024, driven by growth in both Med Tech and Med Device portfolios. The company completed the sale of its PICC and Midline product portfolios and reached a settlement agreement with BD/Bard. They also received FDA 510(k) clearance for AlphaVac in the treatment of pulmonary embolism.
Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024.
Pro forma net sales increased 8.0% to $66.0 million.
Pro forma Med Tech net sales increased 12.6%.
Subsequent to quarter end, the Company received 510(k) clearance for the use of AlphaVac to treat pulmonary embolism
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company now expects its fiscal year 2024 net sales to be in the range of $270 to $275 million, expects gross margin to be approximately 52.0% to 54.0% and adjusted loss per share in the range of $0.54 to $0.58.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...